1-10 of 10
Rafal Dziadziuszko
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors

George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2196.
https://doi.org/10.1158/1078-0432.CCR-22-1108
Published: 13 May 2022
View article titled, Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with <em>NTRK</em> Fusion–Positive Solid Tumors
Open the PDF for Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with <em>NTRK</em> Fusion–Positive Solid Tumors in another window
Journal Articles

Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial

Rafal Dziadziuszko, Solange Peters, Tony Mok, D. Ross Camidge, Shirish M. Gadgeel, Sai-Hong Ignatius Ou, Krzysztof Konopa, Johannes Noé, Malgorzata Nowicka, Walter Bordogna, Peter N. Morcos, Vlatka Smoljanovic, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (9): 1800–1808.
https://doi.org/10.1158/1078-0432.CCR-21-2840
Published: 02 May 2022
View article titled, Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <em>ALK</em>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
Open the PDF for Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <em>ALK</em>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial in another window
Includes: Supplementary data
Journal Articles

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1302–1312.
https://doi.org/10.1158/1078-0432.CCR-21-3597
Published: 01 April 2022
View article titled, Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <em>NTRK</em> Fusion-Positive Solid Tumors
Open the PDF for Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <em>NTRK</em> Fusion-Positive Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

Caroline E. McCoach, Anh T. Le, Katherine Gowan, Kenneth Jones, Laura Schubert, Andrea Doak, Adriana Estrada-Bernal, Kurtis D. Davies, Daniel T. Merrick, Paul A. Bunn, Jr, W. Tom Purcell, Rafal Dziadziuszko, Marileila Varella-Garcia, Dara L. Aisner, D. Ross Camidge, Robert C. Doebele
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (14): 3334–3347.
https://doi.org/10.1158/1078-0432.CCR-17-2452
Published: 15 July 2018
View article titled, Resistance Mechanisms to Targeted Therapies in <em>ROS1</em><sup>+</sup> and <em>ALK</em><sup>+</sup> Non–small Cell Lung Cancer
Open the PDF for Resistance Mechanisms to Targeted Therapies in <em>ROS1</em><sup>+</sup> and <em>ALK</em><sup>+</sup> Non–small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

Murry W. Wynes, Trista K. Hinz, Dexiang Gao, Michael Martini, Lindsay A. Marek, Kathryn E. Ware, Michael G. Edwards, Diana Böhm, Sven Perner, Barbara A. Helfrich, Rafal Dziadziuszko, Jacek Jassem, Szymon Wojtylak, Aleksandra Sejda, Joseph M. Gozgit, Paul A. Bunn, Jr, D. Ross Camidge, Aik-Choon Tan, Fred R. Hirsch, Lynn E. Heasley
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (12): 3299–3309.
https://doi.org/10.1158/1078-0432.CCR-13-3060
Published: 12 June 2014
View article titled, FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
Open the PDF for FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies in another window
Includes: Supplementary data
Journal Articles

Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer

Dylan M. Glubb, Elisa Cerri, Alexandra Giese, Wei Zhang, Osman Mirza, Emma E. Thompson, Peixian Chen, Soma Das, Jacek Jassem, Witold Rzyman, Mark W. Lingen, Ravi Salgia, Fred R. Hirsch, Rafal Dziadziuszko, Kurt Ballmer-Hofer, Federico Innocenti
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (16): 5257–5267.
https://doi.org/10.1158/1078-0432.CCR-11-0379
Published: 14 August 2011
View article titled, Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer
Open the PDF for Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer

Fred R. Hirsch, Marileila Varella-Garcia, Rafal Dziadziuszko, Yun Xiao, Sujatha Gajapathy, Margaret Skokan, Ming Lin, Vincent O'Neill, Paul A. Bunn, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19): 6317–6323.
https://doi.org/10.1158/1078-0432.CCR-08-0539
Published: 30 September 2008
View article titled, Fluorescence <em>In situ</em> Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer
Open the PDF for Fluorescence <em>In situ</em> Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer in another window
Journal Articles

Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

Rafal Dziadziuszko, Fred R. Hirsch, Marileila Varella-Garcia, Paul A. Bunn, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4409s–4415s.
https://doi.org/10.1158/1078-0432.CCR-06-0087
Published: 20 July 2006
View article titled, Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence <em>In situ</em> Hybridization—Why, When, and How?
Open the PDF for Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence <em>In situ</em> Hybridization—Why, When, and How? in another window
Journal Articles

Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

Paul A. Bunn, Jr., Rafal Dziadziuszko, Marileila Varella-Garcia, Wilbur A. Franklin, Samir E. Witta, Karen Kelly, Fred R. Hirsch
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (12): 3652–3656.
https://doi.org/10.1158/1078-0432.CCR-06-0261
Published: 15 June 2006
View article titled, Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Open the PDF for Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in another window
Journal Articles

Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer

Rafal Dziadziuszko, Samir E. Witta, Federico Cappuzzo, Seongjin Park, Koji Tanaka, Peter V. Danenberg, Anna E. Barón, Lucio Crino, Wilbur A. Franklin, Paul A. Bunn, Jr., Marileila Varella-Garcia, Kathleen D. Danenberg, Fred R. Hirsch
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (10): 3078–3084.
https://doi.org/10.1158/1078-0432.CCR-06-0106
Published: 17 May 2006
View article titled, Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer
Open the PDF for Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer in another window